Explore why Deutsche Bank has downgraded Intuitive Surgical to ‘Sell’. Discover the implications for investors and market reactions.
In a recent communication with clients, Deutsche Bank analysts have revised their rating for Intuitive Surgical (NASDAQ: ISRG) from ‘Neutral’ to ‘Sell’. Additionally, they have adjusted their target price for the stock from $515 down to $440.
As a result of this announcement, ISRG shares have experienced a decline of over 5% in today’s trading session, although they remain above the $525.50 mark.
To further comprehend the situation, the bank will be conducting an investor webinar on Monday, June 9. This event will feature Jon Reuter, COO of USC Keck Hospitals. The focus of the call will be on understanding Intuitive’s hospital clients’ perspectives regarding the adoption of its remanufactured Endowrist instruments.
Deutsche Bank has informed investors that Intuitive Surgical may soon face intensified competition. While the firm remains “extremely confident about the sustained dominance of da Vinci surgery over the forthcoming years,” it acknowledged the emergence of several competing robotic systems. Notably, the FDA is expected to approve Medtronic’s Hugo by late 2025, which could potentially challenge ISRG’s competitive edge.
Despite the downgrade, Deutsche Bank praised Intuitive’s da Vinci platform as “one of the most disruptive innovations in the history of medical technology.” The firm also highlighted the remarkable performance of ISRG’s stock, which has surged more than 26,000% since its IPO in 2000, compared to the S&P 500’s nearly 500% return. They noted that ISRG remains a favored long-term investment position.
Yorum Yap